Connect with others who understand.

  •   Learn from expert-reviewed resources
  •   Real advice from people who’ve been there
  •   People who understand what you’re going through
Sign Up Log In
All Resources Treatments A-Z Personal Assistant What is This Site Help Center Crisis
Powered By

Top 6 search results for "Tepmetko" in Resources. To see all results and access other features, sign up for free.

Posts
Resources
Q&A
People
Groups
Treatments
2021 Highlight: FDA Expanded Lung Cancer Treatment Options With Four New Drugs
... Food and Drug Administration MET Oncogene in Non-Small Cell Lung Cancer: Mechanism of MET Dysregulation and Agents Targeting the HGF/c-Met Axis — OncoTargets and Therapy MET Exon 14 Skipping: A Case Study for the Detection of Genetic Variants in Cancer Driver Genes by Deep Learning — International Journal of Molecular Sciences FDA Approves Tepmetko ...
Posted 01/04/2022
2021 Highlight: FDA Expanded Lung Cancer Treatment Options With Four New Drugs
... Food and Drug Administration MET Oncogene in Non-Small Cell Lung Cancer: Mechanism of MET Dysregulation and Agents Targeting the HGF/c-Met Axis — OncoTargets and Therapy MET Exon 14 Skipping: A Case Study for the Detection of Genetic Variants in Cancer Driver Genes by Deep Learning — International Journal of Molecular Sciences FDA Approves Tepmetko ...
Posted 01/04/2022
Lung Cancer Developments in 2021 Offer Hope for the Future
... Food and Drug Administration FDA Approves Tepmetko as the First and Only Once-Daily Oral MET Inhibitor for Patients With Metastatic NSCLC With METex14 Skipping Alterations — Merck KGaA FDA Approves First Targeted Therapy for Subset of Non-Small Cell Lung Cancer — U.S. Food and Drug Administration Guardant360 CDx — P200010/S001 — U.S. ...
Posted 01/11/2022
Lung Cancer Developments in 2021 Offer Hope for the Future
... Food and Drug Administration FDA Approves Tepmetko as the First and Only Once-Daily Oral MET Inhibitor for Patients With Metastatic NSCLC With METex14 Skipping Alterations — Merck KGaA FDA Approves First Targeted Therapy for Subset of Non-Small Cell Lung Cancer — U.S. Food and Drug Administration Guardant360 CDx — P200010/S001 — U.S. ...
Posted 01/11/2022
NSCLC Targeted Therapy: 8 Facts
... Repotrectinib (Augtyro) Taletrectinib (Ibtrozi) BRAF inhibitors Dabrafenib (Tafinlar) Encorafenib (Braftovi) Vemurafenib (Zelboraf) MEK inhibitors Binimetinib (Mektovi) Trametinib (Mekinist) RET inhibitors Cabozantinib (Cometriq, Cabometyx) Pralsetinib (Gavreto) Selpercatinib (Retevmo) MET inhibitors Capmatinib (Tabrecta) Crizotinib Tepotinib (Tepmetko ...
NSCLC Targeted Therapy: 8 Facts
... Repotrectinib (Augtyro) Taletrectinib (Ibtrozi) BRAF inhibitors Dabrafenib (Tafinlar) Encorafenib (Braftovi) Vemurafenib (Zelboraf) MEK inhibitors Binimetinib (Mektovi) Trametinib (Mekinist) RET inhibitors Cabozantinib (Cometriq, Cabometyx) Pralsetinib (Gavreto) Selpercatinib (Retevmo) MET inhibitors Capmatinib (Tabrecta) Crizotinib Tepotinib (Tepmetko ...
Biomarkers for Lung Cancer: 12 Things To Know
... These treatments include: Capmatinib (Tabrecta) Telisotuzumab vedotin (Emrelis) Tepotinib (Tepmetko) 7. KRAS G12C Mutations Have Two Approved Targeted DrugsKRAS G12C is a biomarker seen in about 13 percent of advanced non-small cell lung cancers. ...
Biomarkers for Lung Cancer: 12 Things To Know
... These treatments include: Capmatinib (Tabrecta) Telisotuzumab vedotin (Emrelis) Tepotinib (Tepmetko) 7. KRAS G12C Mutations Have Two Approved Targeted DrugsKRAS G12C is a biomarker seen in about 13 percent of advanced non-small cell lung cancers. ...
NSCLC Treatment Options: First-Line Treatments and Beyond
... ceritinib (Zykadia), crizotinib (Xalkori), entrectinib (Rozlytrek), repotrectinib (Augtyro), and taletrectinib (Ibtrozi) BRAF inhibitors, such as dabrafenib (Tafinlar), encorafenib (Braftovi), and vemurafenib (Zelboraf) RET inhibitors, such as pralsetinib (Gavreto) and selpercatinib (Retevmo) MET inhibitors, such as capmatinib (Tabrecta) and tepotinib (Tepmetko ...
NSCLC Treatment Options: First-Line Treatments and Beyond
... ceritinib (Zykadia), crizotinib (Xalkori), entrectinib (Rozlytrek), repotrectinib (Augtyro), and taletrectinib (Ibtrozi) BRAF inhibitors, such as dabrafenib (Tafinlar), encorafenib (Braftovi), and vemurafenib (Zelboraf) RET inhibitors, such as pralsetinib (Gavreto) and selpercatinib (Retevmo) MET inhibitors, such as capmatinib (Tabrecta) and tepotinib (Tepmetko ...
Lung Cancer Treatment Options
... Tepotinib hydrochloride (Tepmetko) also blocks the function of MET proteins.Additionally, in 2025, the FDA approved telisotuzumab vedotin-tllv (Emrelis), an antibody-drug conjugate for treating metastatic non-squamous NSCLC with high c-Met protein overexpression in people who have received prior therapy. ...
Lung Cancer Treatment Options
... Tepotinib hydrochloride (Tepmetko) also blocks the function of MET proteins.Additionally, in 2025, the FDA approved telisotuzumab vedotin-tllv (Emrelis), an antibody-drug conjugate for treating metastatic non-squamous NSCLC with high c-Met protein overexpression in people who have received prior therapy. ...